Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more
Minerva Neurosciences Inc (NERV) - Net Assets
Latest net assets as of September 2025: $-34.58 Million USD
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has net assets worth $-34.58 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.09 Million) and total liabilities ($62.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-34.58 Million |
| % of Total Assets | -123.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | -148.79% |
| 10-Year Change | -146.44% |
| Growth Volatility | 31806.59 |
Minerva Neurosciences Inc - Net Assets Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Minerva Neurosciences Inc (2012–2024)
The table below shows the annual net assets of Minerva Neurosciences Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-25.69 Million | +9.71% |
| 2023-12-31 | $-28.46 Million | -42.12% |
| 2022-12-31 | $-20.02 Million | -351.07% |
| 2021-12-31 | $7.98 Million | -84.86% |
| 2020-12-31 | $52.66 Million | +89.57% |
| 2019-12-31 | $27.78 Million | -69.22% |
| 2018-12-31 | $90.26 Million | -31.41% |
| 2017-12-31 | $131.60 Million | +24.17% |
| 2016-12-31 | $105.98 Million | +91.58% |
| 2015-12-31 | $55.32 Million | +7.42% |
| 2014-12-31 | $51.50 Million | +155.21% |
| 2013-12-31 | $20.18 Million | +106002.33% |
| 2012-12-31 | $19.02K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Minerva Neurosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38080877700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $699.00 | % |
| Other Components | $369.68 Million | % |
| Total Equity | $-25.69 Million | 100.00% |
Minerva Neurosciences Inc Competitors by Market Cap
The table below lists competitors of Minerva Neurosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wisekey International Holding AG
NASDAQ:WKEY
|
$26.93 Million |
|
NORSK TITANIUM NK-08
F:84F
|
$26.93 Million |
|
centrotherm international AG
F:CTNK
|
$26.94 Million |
|
E&E Recycling
TWO:8440
|
$26.94 Million |
|
HOFFMANN GR.CEM.TEC. 1-
F:0VW
|
$26.92 Million |
|
Bank Victoria International
JK:BVIC
|
$26.92 Million |
|
S-Fuelcell co. Ltd
KQ:288620
|
$26.91 Million |
|
CrownHaitai Holdings Co Ltd Preference Shares
KO:005745
|
$26.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Minerva Neurosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -28,457,490 to -25,693,100, a change of 2,764,390.
- Net income of 1,438,865 contributed positively to equity growth.
- Other factors increased equity by 1,325,525.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.44 Million | +5.6% |
| Other Changes | $1.33 Million | +5.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Minerva Neurosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.01 | $7.85 | x |
| 2013-12-31 | $8.83 | $7.85 | x |
| 2014-12-31 | $22.17 | $7.85 | x |
| 2015-12-31 | $18.90 | $7.85 | x |
| 2016-12-31 | $26.91 | $7.85 | x |
| 2017-12-31 | $27.75 | $7.85 | x |
| 2018-12-31 | $18.61 | $7.85 | x |
| 2019-12-31 | $5.70 | $7.85 | x |
| 2020-12-31 | $10.30 | $7.85 | x |
| 2021-12-31 | $1.49 | $7.85 | x |
| 2022-12-31 | $-3.75 | $7.85 | x |
| 2023-12-31 | $-4.37 | $7.85 | x |
| 2024-12-31 | $-3.39 | $7.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Minerva Neurosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-729.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -8318.00% | 0.00% | 0.00x | 11.01x | $-1.58 Million |
| 2013 | -16.16% | 0.00% | 0.00x | 1.45x | $-5.28 Million |
| 2014 | -110.49% | 0.00% | 0.00x | 1.33x | $-62.05 Million |
| 2015 | -48.96% | 0.00% | 0.00x | 1.49x | $-32.61 Million |
| 2016 | -29.29% | 0.00% | 0.00x | 1.25x | $-41.64 Million |
| 2017 | -23.95% | 0.00% | 0.00x | 1.40x | $-44.68 Million |
| 2018 | -55.58% | 0.00% | 0.00x | 1.54x | $-59.20 Million |
| 2019 | -259.84% | -175.31% | 0.53x | 2.79x | $-74.96 Million |
| 2020 | 3.69% | 4.71% | 0.71x | 1.09x | $-3.33 Million |
| 2021 | -625.73% | 0.00% | 0.00x | 9.67x | $-50.70 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.11 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.16 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $4.01 Million |
Industry Comparison
This section compares Minerva Neurosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Minerva Neurosciences Inc (NERV) | $-34.58 Million | -8318.00% | N/A | $26.92 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |